Embedded Files
Research experience (after PhD): > 24 years
Research Area - Development of Protein Biopharmaceuticals
It is evident now that, in coming decade, the domestic as well as the international market for protein biopharmaceuticals will grow rapidly and will expand its share of the entire pharmaceuticals market. Also, there is a dire need to develop protein biopharmaceuticals to lower the import burden and to make our Nation self-reliant. This may also lower the cost and make these drugs available and more affordable to Jan-Manas (common man). My laboratory is involved in the development of Protein Biopharmaceuticals and the details of my current research programs are summarized below:
Programme 1 – Engineering antibodies and development of antibody-based biopharmaceuticals
In this program we are developing 2nd generation antibodies (PolyBodiesTM) as well as conjugated antibodies (ConBodiesTM) for clinical use.
- BiSpekDAbTM, the first molecule we developed, is a bispecific antibody which targets both IL-23 & TNF-α and attenuates inflammation in animal models of inflammatory conditions (asthma, stroke, and others). (patent # 17). Detailed characterization of BiSpekDAb and other novel PolyBodies as well as ConBodies is currently going on in the lab (patent # 12, 15, 16).
- We are also engage in engineering and development of conjugated antibodies (ConBodiesTM) for therapeutic and diagnostic use.
Programme 2 – Engineering enzymes and development of enzyme-based biopharmaceuticals
In this program we are developing engineered enzymes, which are as follows:
- LBURGINAZE™ is engineered human arginase 1 enzyme. LBURGINAZE exhibit enhanced in vivo pharmacokinetic as well as potent anti-cancer activity in multiple cancer models (patents # 8, 10, 11). We are developing this molecule for the treatment of Liver cancer.
- LBUPONTM is an engineered human paraoxonase 1 enzyme that not only exhibits effective nerve agent-neutralizing activity but also possesses improved (in vivo) pharmacokinetic properties. Further characterization of LBUPONTM is currently going on (in collaboration with DRDE, Gwalior & IRBA, France) (patent # 1, 2, 9, 14).
- We are also developing safe, effective, and environmentally friendly SsoPox enzyme-based nanobioctatalyst for organophosphate decontamination. A panel of microbial enzymes is produced and immobilized on nanomaterials for efficient separation and reuse (patent # 4, 5, 7).
Programme 3 – Engineering peptides and development of peptide-based biopharmaceuticals
In this program we are developing engineered peptides, which are as follows:
- Neuro-ETM is apolipoprotein E-mimicking peptides which exhibit strong anti-inflammatory and neurohealing properties. Neuro-E shows promising results in animal models of inflammation (pulmonary inflammation, cardiac inflammation and neuroinflammation) (patent # 3, 6, 13).
- NGOBLOKER™ is engineered human endostatin molecule and has demonstrated desirable anti-angiogenic activity in the in vivo Chick Chorioallantoic Membrane (CAM) model. It is currently undergoing further characterization studies (patent # 18).
Extramural Projects
Research project handled / Ongoing
Page updated
Google Sites
Report abuse